#Switzerland #CEO #Basel #CordenPharma #Dr. Jean-Luc Herbeaux

CordenPharma Welcomes New Leadership

CordenPharma, a premier global CDMO in the pharmaceutical sector, has announced the significant appointment of Dr. Jean-Luc Herbeaux as its new Chief Executive Officer, effective October 1, 2026. This transition marks a pivotal moment as the company gears up for its next phase of growth and strategic endeavors.

Dr. Herbeaux takes over the leadership reins from Dr. Michael Quirmbach, who has played an instrumental role at CordenPharma since 2014, including serving as CEO since 2019. Under his guidance, the company saw remarkable transformative growth, raising its annual revenue from €245 million to over €1 billion. Following this transition, Dr. Quirmbach will continue contributing to the company as a Board Member and Senior Advisor, allowing him to share his invaluable insights and experience within the industry.

A Seasoned Leader Steps In

Dr. Jean-Luc Herbeaux brings an impressive portfolio of experience to CordenPharma, having previously served as the CEO of Hovione and holding several senior positions at Evonik, a leader in sustainable materials. His depth of knowledge and operational acumen in the pharmaceutical industry positions him well to navigate the challenges and opportunities that lie ahead.

As the new CEO, Dr. Herbeaux is committed to executing CordenPharma's strategic vision, which focuses on operational excellence, industry growth, and strong customer relationships. He anticipates building upon the robust foundation that Dr. Quirmbach established and is excited about the potential ahead. "I am thrilled to join CordenPharma and lead its talented team during this defining phase. We have clear growth plans, and I intend to deepen our partnerships with customers while reinforcing our capabilities to deliver essential medicines globally," he expressed enthusiastically.

The Future of CordenPharma

CordenPharma is undergoing a significant stage of development, further accentuated by strategic expansions such as the recent acquisition of AmbioPharm, a prominent peptide CDMO. This acquisition complements CordenPharma's ongoing investments in manufacturing capacity and capabilities across its extensive facility network, strategically located across the United States, Europe, and Asia.

The company currently employs around 3,500 individuals and is known for its commitment to delivering high-value, tailored solutions encompassing the entire drug development lifecycle—from early-phase clinical development to full-scale commercialization.

CordenPharma’s decision to transition leadership now is seen as a calculated step towards further strengthening its position in the sector. With Dr. Herbeaux at the helm, the organization is poised for continual growth, operational efficiency, and a deeper focus on providing vital support to pharmaceutical innovators.

A Grateful Farewell

Dr. Quirmbach expressed gratitude for his decade-long journey with CordenPharma, highlighting the importance of collaboration and the thriving culture of innovation developed during his tenure. His leadership has fostered a strong customer-centric approach which is crucial in today’s competitive landscape.

Notable figures within CordenPharma, such as Judith Charpentier, Co-Managing Partner and Co-Head of Flagship, acknowledged Dr. Quirmbach's substantial contributions, emphasizing the company’s gratitude for his leadership and the foundations he has set in place for a bright future. As they transition in leadership dynamics, the company remains committed to ensuring that they successfully meet the needs of their customers and maintain their status as leaders in the pharmaceutical development and manufacturing ecosystem.

In conclusion, as CordenPharma looks ahead under the guidance of Dr. Jean-Luc Herbeaux, stakeholders and industry observers alike will undoubtedly be watching closely as the company embarks on this promising new chapter in its illustrious journey.

• ---

For more information, visit CordenPharma's official website.